Skip to main content
Fig. 3 | BMC Medical Research Methodology

Fig. 3

From: Community Assessment of COPD Health Care (COACH) study: a clinical audit on primary care performance variability in COPD care

Fig. 3

Distribution of maintenance inhaled therapies according to GOLD 2017 groups. Only in 436 cases out of the total 4307 cases audited (10.1%), GOLD classification could be assessed, based on exacerbation frequency and symptoms. ICS: inhaled corticosteroids; LABA: long-acting ß2 agonist; LABD: long-acting bronchodilator; LAMA: long-acting muscarinic antagonist; CAT: COPD Assessment Test; mMRC: modified Medical Research Council

Back to article page